• AngioDynamics granted sign-on restricted stock units to Eric Honroth on November 2, 2026, effective with his appointment as CEO.
• The first award covers 62,928 shares, vesting in equal annual installments over four years, subject to continued service.
• Performance-based restricted stock units cover 62,928 shares at target, with payouts ranging from 0% to 240% of target.
• The performance award requires continued service through certification, with three-year targets covering revenue, adjusted EBITDA and relative total shareholder return.
• Another 38,265 time-based restricted stock units vest equally on November 2, 2027, and November 2, 2028, subject to continued service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261106038551) on November 06, 2026, and is solely responsible for the information contained therein.